Leukemia drug combo is encouraging in early phase I clinical trial

In a Phase I study, 8 out of 12 patients with relapsed and/or chemotherapy refractory blood cancers responded to a combination of the chemotherapy drugs thioguanine and decitabine; some of the responders had relapsed after treatment with decitabine alone, report researchers.